The Phase 3 start timing for AP-SA02 is the key catalyst; monitor FDA protocol concurrence and any further non-dilutive funding announcements. The convertible loan fair value gain is non-recurring and does not reflect operational improvement.
Drugs in focus
ARMP drug pipeline →AP-SA02
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2 complete; Phase 3 (registrational) planned for H2 2026
- Time to market
- Phase 3 (registrational) initiation expected H2 2026; pivotal data and any BLA/approval are realistically 2028-2030 at the earliest, contingent on Phase 3 success — AP-SA02 is years from commercialization.
- Next catalyst
- None dated
What to watchWatch for confirmation of the Phase 3 start (H2 2026 window) and any financing announcement, because the ~$5.07 stock's biggest near-term risks are cash runway and dilution, not trial mechanics. The real share-price binary, Phase 3 topline data, is likely 2+ years out, so treat the gap between the stock and the ~$17.5 mean analyst target as a long-dated optionality play, not a near-term event.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $3.87entry
- T+1 · 17h ago −22.74%α −20.83% · $2.99
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Armata Pharmaceuticals reported Q3 2026 GAAP net income of $54.9M ($1.15 basic EPS, $(0.24) diluted EPS), driven by a $69.6M non-cash gain from convertible loan fair value change. Operating loss narrowed to $7.4M from $7.8M a year ago. The company is preparing for a Phase 3 study of AP-SA02, which received FDA Breakthrough Therapy designation, and received $3.7M in non-dilutive DoW funding. Consensus EPS of $(0.56) was not met on a GAAP basis; the diluted loss per share of $(0.24) compares to a consensus estimate of $(0.56), representing a beat of 57.1%.
Key Financial Metrics
Key Facts
- Q3 2026 net income $54.9M vs net loss $(26.7M) in Q3 2025, driven by $69.6M gain from convertible loan fair value change
- Diluted EPS $(0.24) vs consensus $(0.56), beat of 57.1%
- Operating loss improved to $7.4M from $7.8M in Q3 2025
- Grant and award revenue $3.2M, up from $1.2M in Q3 2025
- Cash and equivalents $18.3M as of Sep 30, 2026, up from $8.7M at Dec 31, 2025
- Received FDA Breakthrough Therapy designation for AP-SA02
- Received $3.7M in non-dilutive DoW funding for Phase 3 preparation
- Phase 3 study of AP-SA02 expected to initiate in H2 2026, pending FDA protocol concurrence
- Two new U.S. patents issued for AP-SA02 and AP-PA02
Financial Impact
Net income of $54.9M primarily from non-cash fair value gain; operating cash burn of $(20.0M) in 9M 2026; cash position $18.3M
Risk Factors
- Net income driven by non-cash fair value gain, not operational profitability
- Cash burn continues with $20.0M used in operations over 9 months; $18.3M cash may require additional financing before Phase 3 completion
- Phase 3 initiation dependent on FDA protocol agreement, timeline uncertain
- Diluted share count of 62.7M reflects convertible loan dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302938272 |
Track record
6 reports on ARMP
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +43.90% at T+60 after the May 13, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 5/10 Viewing Entry $3.87 Now $2.99 −22.74% settles Dec 14
- Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
- Jul 20, 202617w ago 8-K Bullish 5/10 Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
- May 13, 202626w ago 8-K Bearish 6/10 Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
- Apr 27, 202629w ago 8-K Neutral 3/10 Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers